Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Allergan plc

Since 2012, No Shortage Of Variety In US OTC Switches While Short Of Chronic Conditions

From intranasal corticosteroids to a lice treatment, and from an addition to the OTC PPI market to the first nonprescription acne drug reaching the market through an NDA, US OTC switches in the past 10 years, since FDA began considering widening switch opportunities, haven’t lacked for variety.

FDA Prescription To OTC Switch

Finance Watch: Venture Floodgates Open With New Funds, Dozens Of Rounds

Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.

Financing Innovation

Prior Bad Conduct By Pharma Companies Could Be ‘Plus Factor’ In Merger Review

Experts suggest US FTC and DOJ retrospectively assess whether a merger gives companies increased leverage with PBMs and consider how it will impact vulnerable communities. Rutger’s Michael Carrier says there should be a presumption against mergers between two large firms.

M & A Enforcement

Pharma Mergers: FTC Should Consider Monitoring R&D, Assessing PBM Contracts, Experts Advise

Panelists at FTC/DOJ workshop suggest new remedies to ensure pharma mergers are not anti-competitive. The commission should support scientists and ensure R&D continues, one expert says.

Enforcement Legal Issues
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
  • Other Names / Subsidiaries
    • Actavis, Inc.
    • Actavis plc
    • Akarna Therapeutics Ltd.
    • Allergan, Inc.
    • Anterios, Inc.
    • Arrow Group (Subsidiaries: Arrow Generics (U.K), Cobalt Group (U.S.))
    • AqueSys, Inc.
    • Bonti, Inc.
    • Chase Pharmaceuticals Corporation, Inc.
    • Durata Therapeutics
    • Elastagen Pty Ltd
    • EndoArt SA
    • Envy Medical, Inc.
    • Forest Laboratories [Aptalis Pharmaceutical Technologies
    • (Axcan Pharma, Inc.
    • Eurand N.V.
    • Mpex Pharmaceuticals, Inc.)
    • Cerexa, Inc.
    • Clinical Data, Inc.]
    • Furiex Pharmaceuticals, Inc. (PPD, Inc.)
    • Kythera Biopharmaceuticals, Inc.
    • MAP Pharmaceuticals
    • Motus Therapeutics, Inc. (Rhythm Health, Inc.)
    • Naurex, Inc.
    • Oculeve
    • Regado Biosciences, Inc.
    • RetroSense Therapeutics, LLC
    • Silom Medical Company
    • Uteron Pharma SA
    • Warner Chilcott PLC (Galen Holdings PLC)
    • Watson Pharmaceuticals, Inc.
    • Tobira Therapeutics, Inc.
    • Topokine Therapeutics
    • Vitae Pharmaceuticals, Inc.
    • ForSight VISION5, Inc.
    • LifeCell Corporation
    • ZELTIQ Aesthetics, Inc.
    • Zonagen, Inc.
    • Repros Therapeutics, Inc.
UsernamePublicRestriction

Register